Event Materials 10
Preliminary Findings From the Phase 2 EPPIK Study of Sparsentan in Pediatric Patients With Selected Proteinuric Glomerular Diseases
Sparsentan vs Irbesartan in Patients With Focal Segmental Glomerulosclerosis (FSGS): Results From the Phase 3 DUPLEX Trial
Pivotal Results of the Phase 3 PROTECT Trial of Sparsentan vs Irbesartan in Patients With Immunoglobulin A Nephropathy
Rate of Loss of eGFR and Time-Averaged Proteinuria in IgAN Patients Progressing From Early Stage Disease to Kidney Failure
Concomitant Sparsentan and Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Patients With IgA Nephropathy (IgAN) in the PROTECT Open-Label Extension (OLE)
Sparsentan and Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2is) in the PROTECT Open-Label Extension (OLE) Substudy and SPARTACUS: Trials in Progress
Sparsentan as First-Line Treatment of Incident Patients With IgA Nephropathy: Preliminary Findings From the SPARTAN Trial
Proteinuria and kidney survival in focal segmental glomerulosclerosis (FSGS) or immunoglobulin A nephropathy (IgAN): A NEPTUNE analysis
Predictors of Major Adverse Kidney Disease Events in a Real-World Population With IgA Nephropathy
Contact Us
For more information, please click on the link below to be directed to our contact us form.
Adverse Event Reporting
To report suspected adverse reactions, contact Travere Therapeutics at 1-877-659-5518 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.